<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious" exact="infection" post="that may break the healthcare system of several countries."/>
 <result pre="new treatments based on current knowledge of the mechanism of" exact="infection" post="and potential targets within. Finally, we also discuss patent"/>
 <result pre="the best alternative, indicating that enhanced public health interventions, including" exact="social distancing," post="use of masks and movement restrictions should be implemented"/>
 <result pre="be implemented to bring the COVID-19 pandemic under control. Aggressive" exact="isolation" post="measures including travel restriction in China, have successfully led"/>
 <result pre="using a post-pandemic mathematical model.9 The authors demonstrated that social" exact="isolation" post="will be necessary at the best scenario until 2021,"/>
 <result pre="OC43, and HKU1 can cause upper and lower respiratory tract" exact="infection" post="in adults and children. After the 2000s, two epidemic"/>
 <result pre="following topic, we will review SARS-CoV-2 structure and mechanism of" exact="infection" post="in order to discuss molecular targets from the virus"/>
 <result pre="been carried out so far for COVID-19 treatment. Finally, as" exact="treatment" post="availability is of utmost importance when dealing with a"/>
 <result pre="are more advanced in clinical studies. SARS-CoV-2: structure, mechanism of" exact="infection" post="and drug targets SARS-CoV-2 structure - Electron microscopy imaging"/>
 <result pre="instance, the stabilisation of N protein-RNA complexes.56,63 SARS-CoV-2 mechanism of" exact="infection" post="- At present, the mechanisms that underlie SARS-CoV-2 infection"/>
 <result pre="of infection - At present, the mechanisms that underlie SARS-CoV-2" exact="infection" post="have not been directly described. Nonetheless, they seem to"/>
 <result pre="to those proposed for other coronaviruses.58 In one proposal, virus" exact="infection" post="starts with the binding of its S proteins to"/>
 <result pre="replication cycle and potential targets for drug repurposing. (1) Virus" exact="infection" post="initiates with the binding of virus S proteins to"/>
 <result pre="exocytosis.48,56,59 Candidate drug targets - In the search for a" exact="treatment" post="for COVID-19, several viral and host molecular proteins have"/>
 <result pre="targets. Overall, they participate in key events of the virus" exact="infection" post="cycle, such as cell entry and replication, as well"/>
 <result pre="response of the host.85 These functions are pivotal for virus" exact="infection" post="justifying the search for SARS-CoVs PLpro inhibitors.84,86,87,88,89,90 Putative inhibitors"/>
 <result pre="fostamatinib disodium (6) (a tyrosine kinase inhibitor used in the" exact="treatment" post="of chronic immune thrombocytopenia) and natural products [e.g., platycodin"/>
 <result pre="favipiravir (9), a purine nucleic acid analog used in the" exact="treatment" post="of influenza, and ribavirin (10), a synthetic guanosine nucleoside"/>
 <result pre="and ribavirin (10), a synthetic guanosine nucleoside indicated for the" exact="treatment" post="of hepatitis C virus (HCV) infection.97,98 The crucial role"/>
 <result pre="[e.g., bismuth potassium citrate (14), a compound used in clinical" exact="treatment" post="of gastrointestinal diseases].103,104,106 Fig. 7: tertiary structure of severe"/>
 <result pre="proteins.126 Host cell targets - A key step in SARS-CoVs" exact="infection" post="is the attachment of S protein to host angiotensin-converting"/>
 <result pre="interesting therapeutic target since its inhibitors could potentially block virus" exact="infection" post="in its initial stages.65,138 Potential TMPRSS2 blockers include some"/>
 <result pre="exogenous or membrane-bound proteases (e g. TMPRSS2) to promote SARS-CoVs" exact="infection" post="on cellsâ€™ surface, the virus can also be internalised"/>
 <result pre="a therapeutic effect in inflammatory diseases.145,146 Their use in COVID-19" exact="treatment" post="may be beneficial to avoid the â€œcytokines stormâ€� syndrome"/>
 <result pre="its release from infected cells.150 Its critical role in virus" exact="infection" post="and proliferation has been exploited by NA inhibitors [e.g.,"/>
 <result pre="DDP4 inhibitors, such as sitagliptin (29) (anti-diabetic drug), in the" exact="treatment" post="of COVID-19.152,153,155,156 In principle, these inhibitors could be beneficial"/>
 <result pre="to prove this hypothesis.152,153,156 Repositioning studies in progress for the" exact="treatment" post="of COVID-19 Computational approaches - The SARS-CoV-2 pandemic is"/>
 <result pre="and results. Smith and Smith performed a large virtual high-throughput" exact="screening" post="to identify drugs, natural products and metabolites that could"/>
 <result pre="the selected molecules and targets have reported links to viral" exact="infection" post="and some have been used for treatment of Coronavirus-related"/>
 <result pre="links to viral infection and some have been used for" exact="treatment" post="of Coronavirus-related disease, such as emodin (44) in SARS-CoV,"/>
 <result pre="demonstrates that we did not learn a suitable strategy for" exact="treatment" post="from these two prior diseases, and we are not"/>
 <result pre="signs, viral replication and pathology reported in humans.193In vivo animal" exact="infection" post="experiments with SARS-CoV-2 require infrastructure of a biosafety level"/>
 <result pre="to 100.8 / 14.4 to 61.5 depending on multiplicities of" exact="infection" post="194,195,196 Ritonavir (2) + lopinavir (1) HIV 3-chymotrypsin-like protease"/>
 <result pre="of varying concentrations of Remdesivir (8).194 This compound blocked virus" exact="infection" post="at low-micromolar concentration (EC50 = 0.77 Î¼M) and showed"/>
 <result pre="100). The authors also disclosed that remdesivir (8) inhibited virus" exact="infection" post="efficiently in human liver cancer Huh-7 cells. Chloroquine (CQ;"/>
 <result pre="(26) is also being studied in vitro as a SARS-CoV-2" exact="infection" post="inhibitor acting on both virus entry, as well as"/>
 <result pre="the two compounds against an in vitro model of SARS-CoV-2" exact="infection" post="on Vero E6 cells, demonstrated that CQ (20) is"/>
 <result pre="more potent than HCQ (26) at four different multiplicities of" exact="infection" post="(0.01, 0.02, 0.2 and 0.8): EC50 2.71, 3.81, 7.14"/>
 <result pre="copy numbers in the cell supernatant at 48 h post" exact="infection" post="were measured. The authors also measured the cytotoxicity of"/>
 <result pre="more potent than CQ (20) to inhibit in vitro SARS-CoV-2" exact="infection" post="(EC50 0.72 vs 5.47 Î¼M).196 The authors also performed"/>
 <result pre="(2)/lopinavir (1) is used together with other antiretrovirals for the" exact="treatment" post="of human immunodeficiency virus since the beginning of the"/>
 <result pre="pipeline comprising in vitro, and in vivo models of SARS-CoV-2" exact="infection" post="is particularly important to identify new antivirals for human"/>
 <result pre="unveiled, until the publication of this manuscript, focusing on COVID-19" exact="treatment" post="interventions (Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-19). With a growing number of"/>
 <result pre="(WHO) organised a simplified dynamic platform comparing the effectiveness of" exact="treatment" post="strategies around the globe. This clinical trial design, called"/>
 <result pre="1063 patients Remdesivir (8) treated patients with lower respiratory tract" exact="infection" post="have a shorter time to recovery compared to placebo"/>
 <result pre="14 days No benefit was observed with lopinavir (1)-ritonavir (2)" exact="treatment" post="compared to standard care in severe Covid-19 patients 220"/>
 <result pre="by inhibiting RNA synthesis, is already in clinical studies for" exact="treatment" post="of COVID-19.96 This prodrug was already investigated in clinical"/>
 <result pre="of COVID-19.96 This prodrug was already investigated in clinical trial" exact="testing" post="for Ebola virus with no effect but showed efficiency"/>
 <result pre="first COVID-19 patient diagnosed in the United States by intravenous" exact="treatment" post="and improved patient clinical condition.222 Grein et al. reported"/>
 <result pre="performed by Beigel et al. (with the same dosage and" exact="treatment" post="period than the previous works cited above) enrolled 1063"/>
 <result pre="conducted to address the effect of remdesivir (8) on COVID-19" exact="treatment" post="(Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-19&amp;amp;term=remdesivir&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist=). Other Phase III clinical trials evaluated"/>
 <result pre="from: https://clinicaltrials.gov/ct2/results?cond=COVID-19&amp;amp;term=remdesivir&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist=). Other Phase III clinical trials evaluated for COVID-19" exact="treatment" post="included CQ (20)/HCQ (26). These studies were endorsed by"/>
 <result pre="(20) base) per day, for ten consecutive days on the" exact="treatment" post="of COVID-19 were performed.217 Based on results for a"/>
 <result pre="al. with a small sample size demonstrated that HCQ (26)" exact="treatment" post="daily at 600 mg significantly decreases viral load in"/>
 <result pre="or HCQ (26, combined or not with a macrolide) for" exact="treatment" post="of COVID-19.229 The observational study verified that with COVID-19"/>
 <result pre="of SARS-CoV to (1)/(2) have already been reported, encouraging its" exact="testing" post="in SARS-CoV-2.235 A total of 199 patients confirmed severe"/>
 <result pre="in SARS-CoV-2.235 A total of 199 patients confirmed severe SARS-CoV-2" exact="infection" post="were randomly designated to be given either (1)/(2) (400"/>
 <result pre="and should decide whether these drugs are useful for COVID-19" exact="treatment" post="or not. Ritonavir (2)/lopinavir (1) plus interferon-beta, a cytokine"/>
 <result pre="1a, compared to interferon beta 1b and the base therapeutic" exact="treatment" post="in Moderate to Severe COVID-19. Currently, there is a"/>
 <result pre="the world examining drugs that can be used for the" exact="treatment" post="of COVID-19. Unfortunately, until this moment no therapeutic options"/>
 <result pre="with randomised, double-blind, placebo-controlled are still needed. Infection prevention by" exact="social distancing" post="and supportive medical care, are the only strategies to"/>
 <result pre="obstacles for effective adoption of a repurposed drug to widespread" exact="treatment" post="of COVID-19. Both patent protection and scalability of manufacturing"/>
 <result pre="shown promising results as a suitable repurposed drug in the" exact="treatment" post="of the COVID-19 disease. Indeed, there are many ongoing"/>
 <result pre="applied for a patent on Gileadâ€™s remdesivir (8) for the" exact="treatment" post="of coronavirus, in an attempt to protect Chinaâ€™s economic"/>
 <result pre="(Family 2), the use of remdesivir (8) in treating Coronaviridae" exact="infection" post="(Family 3), among other patents that claims the use"/>
 <result pre="other patents that claims the use of (8) for the" exact="treatment" post="of a series of viral infections (Families 3 and"/>
 <result pre="if the (8) is proved to be efficient for the" exact="treatment" post="of COVID-19, Gilead Science is the only pharmaceutical company"/>
 <result pre="pathway and another disclosing the use of (39) in the" exact="treatment" post="of Rheumatoid Arthritis. Both of them will expire in"/>
 <result pre="investigated as a drug that could be used in the" exact="treatment" post="of COVID 19 patients, since its anti-inflammatory activity could"/>
 <result pre="evaluate the efficacy and safety of Baricitinib (39) in the" exact="treatment" post="of COVID 19.244 If the drug succeeds, there will"/>
 <result pre="that have been tested as possible agents in the COVID-19" exact="treatment" post="are off-patent, meaning that generic drug companies already manufacture"/>
 <result pre="drug.247 If any of those drugs become approved for the" exact="treatment" post="of COVID-19, its demand will increase dramatically. Therefore, it"/>
 <result pre="allows a nucleophilic addition-elimination reaction to occur, affording (1) after" exact="treatment" post="with NaHCO3 (Fig. 17). Therefore, it is possible to"/>
 <result pre="cost-effective of the three of them. In conclusion - SARS-CoV-2" exact="infection" post="is a life-threatening disease with such a high transmission"/>
 <result pre="In this scenario, repositioning drugs already in clinical use for" exact="treatment" post="of COVID-19 is an important shortcut, as we have"/>
 <result pre="information on the viral and host proteins involved in the" exact="infection" post="mechanism. This knowledge is essential for allowing researchers to"/>
 <result pre="the drugâ€™s industrial production cost and its impact on final" exact="treatment" post="cost. Gilead, remdesivirâ€™s owner company, has recently signed non-exclusive"/>
 <result pre="the constantly growing scientific knowledge summarised in this review, other" exact="treatment" post="options will be revealed soon enough to help stop"/>
 <result pre="but also data sourceLancet Gastroenterol Hepatol20205653353432246939 6AhmedWAngelNEdsonJBibbyKBivinsAcollab: O'Brien JWFirst confirmed" exact="detection" post="of SARS-CoV-2 in untreated wastewater in Australia a proof"/>
 <result pre="of gammacoronavirus and deltacoronavirusJ Virol20128673995400822278237 13KandeilAGomaaMShehataMEl-TaweelAKayedAEAbiadhAMiddle East Respiratory Syndrome coronavirus" exact="infection" post="in non-camelid domestic mammalsEmerg Microbes Infect20198110310830866764 14TyrrellDABynoeMCultivation of viruses"/>
 <result pre="antiviralsVirus Res2019264223130794895 42BlochEMShohamSCasadevallASachaisBSShazBWintersJLDeployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19J Clin Invest202013062757276532254064 43LiGDe ClercqETherapeutic options for the"/>
 <result pre="first patient diagnosed with COVID-19 in AustraliaMed J Aust20202121045946232237278 48ShereenMAKhanSKazmiABashirNSiddiqueRCOVID-19" exact="infection" post="origin, transmission, and characteristics of human coronavirusesJ Adv Res202024919832257431"/>
 <result pre="implication in COVID-19 therapyBiosci Rep202040618 81WangJFast identification of possible drug" exact="treatment" post="of Coronavirus disease-19 (COVID-19) through computational drug repurposing studyJ"/>
 <result pre="multiple replicative enzymesJ Biol Chem201428937257832579625074927 111SunYWangZTaoJWangYWuAYangZYeast-based assays for the high-throughput" exact="screening" post="of inhibitors of coronavirus RNA cap guanine-N7-methyltransferaseAntiviral Res201410415616424530452 112Ahmed-BelkacemRSutto-OrtizPGuiraudMCanardBVasseur"/>
 <result pre="SARS-CoV nsp14 RNA cap guanine-N7-methyltransferaseEur J Med Chem202020111255711255732563813 113SelvarajCDineshDCPanwarUAbhiramiRBouraESinghSKStructure-based virtual" exact="screening" post="and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14)"/>
 <result pre="a potent anti-SARS-CoV-22020antibodydemonstrates ability to completely inhibit in vitro virus" exact="infection" post="in preclinical studies 131DevauxCARolain J-MColsonPRaoultDNew insights on the antiviral"/>
 <result pre="patients with COVID-19?Eur Heart J202041191801180332196087 138ShenLWMaoHJWuYLTanakaYZhangWTMPRSS2 a potential target for" exact="treatment" post="of influenza virus and coronavirus infectionsBiochimie201714211028778717 139HoffmannMSchroederSKleine-WeberHMÃ¼llerMADrostenCPÃ¶hlmannSNafamostat mesylate blocks"/>
 <result pre="and coronavirus infectionsBiochimie201714211028778717 139HoffmannMSchroederSKleine-WeberHMÃ¼llerMADrostenCPÃ¶hlmannSNafamostat mesylate blocks activation of SARS-CoV-2 new" exact="treatment" post="option for COVID-19Antimicrob Agents Chemother202064617 140IdrisMOYekeenAAAlakanseOSDurojayeOAComputer-aided screening for potential"/>
 <result pre="of SARS-CoV-2 new treatment option for COVID-19Antimicrob Agents Chemother202064617 140IdrisMOYekeenAAAlakanseOSDurojayeOAComputer-aided" exact="screening" post="for potential TMPRSS2 inhibitors: a combination of pharmacophore modeling,"/>
 <result pre="to neurodegenerationTransl Neurodegener201541181826448863 144LiuTLuoSLibbyPShi G-PCathepsin L-selective inhibitors a potentially promising" exact="treatment" post="for COVID-19 patientsPharmacol Ther202021310758710758732470470 145Rose-JohnSInterleukin-6 family cytokinesCold Spring Harb"/>
 <result pre="shared pathways with therapeutic implicationsEndocr Rev2020413457470 152StrolloRPozzilliPDPP4 inhibition: preventing SARS-CoV-2" exact="infection" post="and/or progression of COVID-19?Diabetes Metab Res Rev202010.1002/dmrr.3330 153IacobellisGCOVID-19 and"/>
 <result pre="small-molecule inhibitors against Covid-19J Biomol Struct Dyn2020110 161RichardsonPGriffinITuckerCSmithDOechsleOPhelanABaricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet202039510223e30e3132032529 162BungNKrishnanSRBulusuGRoyA.De novo design of"/>
 <result pre="165KimDEMinJSJangMSLeeJYShinYSParkCMNatural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43" exact="infection" post="of MRC-5 human lung cellsBiomolecules2019911696696 166JoSKimSShinDHKim M-SInhibition of SARS-CoV"/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
 <result pre="in miceSci Transl Med202012541 202de WitEFeldmannFCroninJJordanROkumuraAThomasTProphylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc Natl"/>
 <result pre="acidification by chloroquine analogs as a promising strategy for the" exact="treatment" post="of emerging viral diseasesPharmacol Res Perspect201751e0029328596841 206LiuJCaoRXuMWangXZhangHHuHHydroxychloroquine, a less"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov202061161632194981 207McChesneyEWAnimal toxicity and pharmacokinetics of hydroxychloroquine"/>
 <result pre="a randomised, double-blind, placebo-controlled, multicentre trialLancet2020395102361569157832423584 216BeigelJHTomashekKMDoddLEMehtaAKZingmanBSKalilACet al.Remdesivir for the" exact="treatment" post="of Covid-19 - Preliminary reportN Engl J Med202010.1056/NEJMoa2007764 217GaoJTianZYangXBreakthrough"/>
 <result pre="J Med202010.1056/NEJMoa2007764 217GaoJTianZYangXBreakthrough chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci Trends2020141727332074550 218BorbaMGSValFFASampaioVSAlexandreMAAMeloGCBritoMEffect"/>
 <result pre="(SARS-CoV-2) infectionJAMA Netw Open202034e20885732330277 219GautretPLagier J-CParolaPHoangVTMeddebLMailheMHydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19 results of an open-label non-randomized clinical trialInt"/>
 <result pre="230MehraMRDesaiSSRuschitzkaFPatelAN.RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for" exact="treatment" post="of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31180-6 231BoulwareDRPullenMFBangdiwalaASPastickKALofgrenSMOkaforECet al.A randomized"/>
 <result pre="JF-WYaoYYeung M-LDengWBaoLJiaLTreatment with lopinavir/ritonavir or interferon-ÃŸ1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
 <result pre="SARS-CoV 3CLpro inhibitorsJ Theor Biol2008254486186718706430 235ChuCMRole of lopinavir/ritonavir in the" exact="treatment" post="of SARS initial virological and clinical findingsThorax200459325225614985565 236SheahanTPSimsACLeistSRSchÃ¤ferAWonJBrownAJComparative therapeutic"/>
</results>
